Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T

Background: PSMA-based alpha therapy using (225)Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of (177)Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV) on PSMA PET impacts therapy outcomes and...

Descripción completa

Detalles Bibliográficos
Autores principales: Unterrainer, Lena M., Beyer, Leonie, Zacherl, Mathias J., Gildehaus, Franz J., Todica, Andrei, Kunte, Sophie C., Holzgreve, Adrien, Sheikh, Gabriel T., Herlemann, Annika, Casuscelli, Jozefina, Brendel, Matthias, Albert, Nathalie L., Wenter, Vera, Schmidt-Hegemann, Nina-Sophie, Kunz, Wolfgang G., Cyran, Clemens C., Ricke, Jens, Stief, Christian G., Bartenstein, Peter, Ilhan, Harun, Unterrainer, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138410/
https://www.ncbi.nlm.nih.gov/pubmed/35625683
http://dx.doi.org/10.3390/biomedicines10050946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138410/
https://www.ncbi.nlm.nih.gov/pubmed/35625683
http://dx.doi.org/10.3390/biomedicines10050946

Ejemplares similares